ALGN three-lens brief
Evidence-based stock research on ALGN. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Underperforming SPY by 17.3pp over 30 days. · Debt-to-equity of 2.8 — balance-sheet-heavy.
- Underperforming SPY by 17.3pp over 30 days.
- Analyst mean target $209.07 — 27% above current (14 analysts).
- Debt-to-equity of 2.8 — balance-sheet-heavy.
ALGN closed at $164.54 (-0.75%) as of 2026-05-13. Market cap: $11.78B. P/E (trailing) 27.7. Positives: analyst mean target $209.07 — 27% above current (14 analysts).. Concerns: underperforming SPY by 17.3pp over 30 days.; debt-to-equity of 2.8 — balance-sheet-heavy.. Last quarter: Revenue $1.04B, net income $112.77M, free cash flow $538.98M.
Why three lenses on ALGN, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ALGNacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/ALGN" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ALGN brief"></iframe>